Clinical trials: Atezolizumab
Non-small Cell Lung Cancer
A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC
The purpose of this study is to find out whether a brief course of radiation therapy given to one area affected by the cancer will improve the chances of responding to immuno-therapy in the form of a medicine called MPDL3280A, an…
- Trial name
- NCT02463994
- Testing
- MPDL3280A, Hypofractionated Radiotherapy
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of Michigan Rogel Cancer Center
Recurrent Ovarian Carcinoma
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
Atezolizumab in this study is expected to have a positive benefit-risk profile for the treatment of patients with platinum-sensitive relapse of ovarian cancer.
- Trial name
- ANITA (NCT03598270)
- Testing
- Carboplatin, Paclitaxel, Niraparib
- Where
- 71 sites in Belgium, France and 3 more
- Volunteers
- 417 people
- Sponsor
- Grupo Español de Investigación en Cáncer de Ovario
Non Small Cell Lung Cancer, Stage IIIA Lung Cancer
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
This is an open-label, phase II, multi-centre clinical trial. 97 Patients with stage IIIA and IIIB non-small cell lung cancer will be enrolled.
- Conditions
- Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer
- Trial name
- ATHENEA (NCT07153445)
- Testing
- Atezolizumab, Paclitaxel, Carboplatin
- Where
- 21 sites in Spain
- Volunteers
- 97 people
- Sponsor
- Fundación GECP
Metastatic Colorectal Cancer
FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients
The scope of this study is to evaluate the efficacy of the addition of atezolizumab to FOLFOXIRI plus bevacizumab as first line treatment of patients with metastatic colorectal cancer in terms of Progression Free Survival.
- Trial name
- AtezoTRIBE (NCT03721653)
- Testing
- Bevacizumab, Irinotecan, Oxaliplatin
- Where
- Italy
- Volunteers
- 218 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Small Cell Lung Carcinoma
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with…
- Trial name
- NCT05224141
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Etoposide, Cisplatin
- Where
- 140 sites in United States, Argentina and 23 more
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the…
- Conditions
- Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Extrapulmonary Neuroendocrine Carcinoma, Recurrent Extrapulmonary Neuroendocrine Carcinoma, Unresectable Extrapulmonary Neuroendocrine Carcinoma
- Trial name
- NCT05058651
- Testing
- Atezolizumab, Biospecimen Collection, Carboplatin
- Where
- 265 sites in United States
- Volunteers
- 189 people
- Sponsor
- National Cancer Institute (NCI)
SCLC, Extensive Stage
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide
Small cell lung cancer (SCLC) is a rapidly proliferating, neuroendocrine tumor that accounts for about 15% of all lung cancers. Most patients have metastases at primary diagnosis involving sites like bone, adrenal glands, liver…
- Trial name
- SPACE (NCT04221529)
- Testing
- Atezolizumab
- Where
- 19 sites in Austria, Germany
- Volunteers
- 70 people
- Sponsor
- AIO-Studien-gGmbH
Small-cell Lung Cancer, Neoadjuvant Therapy
Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients
This Phase II study was designed to evaluate the safety and efficacy of Atezolizumab in combination with Chemotherapy compared with treatment with Chemotherapy alone in previously untreated Limited-Stage Small Cell Lung Cancer…
- Trial name
- NCT04696939
- Testing
- Atezolizumab, Carboplatin, Etoposide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Non-Small Cell Lung Cancer
A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)
This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC).
- Trial name
- NCT02927301
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody
- Where
- 19 sites in United States
- Volunteers
- 181 people
- Sponsor
- Genentech, Inc.
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
Molecular imaging can be used for the noninvasive assessment of biodistribution of monoclonal antibodies. Atezolizumab has previously successfully been labeled with the radionucleotide Zirconium-89 (89Zr) and studied in solid…
- Trial name
- NCT03850028
- Testing
- 89Zr-atezolizumab PET scans
- Where
- 2 sites in Netherlands
- Sponsor
- University Medical Center Groningen
Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
An Open Label, Multi-Center, Dose Escalation/Expansion, Phase 1/1b Study of IMU 201 (PD1-Vaxx), a B-Cell Immunotherapy as monotherapy or in combination with atezolizumab with or without chemotherapy, in Adults with Non-Small Cell…
- Conditions
- Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Squamous Non-small-cell Lung Cancer
- Trial name
- NCT04432207
- Testing
- IMU-201 (administered as PD1-Vaxx) - Regimen 1, IMU-201 (administered as PD1-Vaxx) - Regimen 2, IMU-201 (administered as PD1-Vaxx) - Regimen 3
- Where
- 6 sites in United States, Australia
- Volunteers
- 24 people
- Sponsor
- Imugene Limited
Recurrent Non-Small Cell Lung Cancer
Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab
This a Phase 1 study designed to determine the maximum tolerated dose (MTD) and toxicity of attenuated Measles virus (MV-NIS) combined with Atezolizumab in patients with recurrent and metastatic NSCLC.
- Trial name
- NCT02919449
- Testing
- MV-NIS, Atezolizumab
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vyriad, Inc.
Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune system fight cancer by blocking proteins that cause cancer cells to grow.
- Conditions
- Locally Advanced Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
- Trial name
- NCT06066138
- Testing
- Atezolizumab
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Glioblastoma Multiforme
A Trial of Ipatasertib in Combination With Atezolizumab
This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose expansion phase (Part B).
- Conditions
- Solid Tumor, Glioblastoma Multiforme, Prostate Cancer Metastatic
- Trial name
- IceCAP (NCT03673787)
- Testing
- ipatasertib, Atezolizumab
- Where
- United Kingdom
- Volunteers
- 87 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Soft Tissue Sarcoma Adult
Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma
This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
- Trial name
- NCT03056599
- Testing
- Multiple drug microinjection, CIVO device
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- Presage Biosciences
Metastatic Cancer, Melanoma Cancer
A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors
Drugs called checkpoint inhibitors help the immune system fight cancer. When the effectiveness of these drugs wears off, it may be possible to renew their effectiveness by combining it with a special type of radiation therapy…
- Conditions
- Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer
- Trial name
- NCT03693014
- Testing
- Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
- Where
- 10 sites in United States
- Volunteers
- 69 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Cholangiocarcinoma, FGFR2 Fusion
Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion
To learn if pemigatinib in combination with atezolizumab and bevacizumab can help to control cholangiocarcinoma.
- Trial name
- NCT06439485
- Testing
- Pemigatinib, Atezolizumab, Bevacizumab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- M.D. Anderson Cancer Center
Small Cell Lung Cancer Extensive Stage, Thoracic Radiotherapy
Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
This is a multicenter phase 2 clinical trial to investigate the treatment efficacy and feasibility of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the upfront treatment of ED SCLC patients.
- Trial name
- TREASURE (NCT04462276)
- Testing
- Atezolizumab, thoracic radiotherapy (TRT)
- Where
- 20 sites in Austria, Germany
- Volunteers
- 68 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
Background: Metastatic colorectal cancer (mCRC) is cancer that has spread beyond the colon and rectum. Most people with mCRC die within 5 years. New immune-based treatments are making progress with some types of colon cancer.
- Conditions
- Microsatellite Stable Metastatic Colorectal Cancer, Metastatic Colorectal Cancer, Colorectal Cancer
- Trial name
- NCT06603818
- Testing
- Tiragolumab, Atezolizumab, Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have…
- Trial name
- STELLAR-303 (NCT05425940)
- Testing
- XL092, Atezolizumab, Regorafenib
- Where
- 133 sites in United States, Australia and 14 more
- Volunteers
- 901 people
- Sponsor
- Exelixis